Li-Min Wang

Li-Min Wang

Auto-generated profile, based on publicly available information

Li-Min Wang

Jiangsu Hengrui Pharmaceuticals Co., Ltd , Jiangsu 222047

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2023 in EMBO Molecular Medicine
Verified
Journal Article
Open access
LWLi‐Min Wang
Li‐Min Wang
PWPingyuan Wang
Pingyuan Wang
XCXiao‐Min Chen
Xiao‐Min Chen
HYHui Yang
Hui Yang
SSShan‐Shan Song
Shan‐Shan Song
JHJin‐Xue He
Jin‐Xue He
Poly‐ADP‐ribose polymerase (PARP) inhibitors (PARPi) have shown great promise for treating BRCA‐deficient tumors. However, over 40% of BRCA‐deficient patients fail to respond to PARPi. Here, we report that thioparib, a next‐generation PARPi with high affinity against multiple PARPs, including PARP1, PARP2, and PARP7, displays high antitumor activities against PARPi‐sensitive and ‐resistant cells with homologous recombination (HR) deficiency both in vitro and in vivo . Thioparib treatment elicited PARP1‐dependent DNA damage and replication stress, causing S‐phase arrest and apoptosis. Conversely, thioparib strongly inhibited HR‐mediated DNA repair while increasing RAD51 foci formation. Notably, the on‐target inhibition of PARP7 by thioparib‐activated STING/TBK1‐dependent phosphorylation of STAT1, triggered a strong induction of type I interferons (IFNs), and resulted in tumor growth retardation in an immunocompetent mouse model. However, the inhibitory effect of thioparib on tumor growth was more pronounced in PARP1 knockout mice, suggesting that a specific PARP7 inhibitor, rather than a pan inhibitor such as thioparib, would be more relevant for clinical applications. Finally, genome‐scale CRISPR screening identified PARP1 and MCRS1 as genes capable of modulating thioparib sensitivity. Taken together, thioparib, a next‐generation PARPi acting on both DNA damage response and antitumor immunity, serves as a therapeutic potential for treating hyperactive HR tumors, including those resistant to earlier‐generation PARPi.

30 November 2021 in Asian Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
LHLeiqiang Han
Leiqiang Han
SLShuang Liang
Shuang Liang
WMWeiwei Mu
Weiwei Mu
ZZZipeng Zhang
Zipeng Zhang
LWLimin Wang
Limin Wang
NZNa Zhang
Na Zhang
Nanomedicine has made great progress in the targeted therapy of cancer. Here, we established a novel drug-mate strategy by studying the formulation of nanodrugs at the molecular level. In the drug-mate combination, the drug is a hydrophobic drug that is poorly soluble in water, and the mate is an amphiphilic small molecule (SMA) that has both hydrophilic and lipophilic properties. We proposed that the hydrophobic drug could co-assemble with a suitable SMA on a nanoscale without additive agents. The proof-of-concept methodology and results were presented to support our hypothesis. We selected five hydrophobic drugs and more than ten amphiphilic small molecules to construct a library. Through molecular dynamic simulation and quantum chemistry computation, we speculated that the formation of nanoassemblies was related to the binding energy of the drug-mate, and the drug-mate interaction must overcome drug-drug interaction. Furthermore, the obtained SF/VECOONa nanoassemblieswas selected as a model, which had an ultra-high drug loading content (46%), improved pharmacokinetics, increased bioavailability, and enhanced therapeutic efficacy. In summary, the drug-mate strategy is an essential resource to design exact SMA for many hydrophobic drugs and provides a reference for the design of a carrier-free drug delivery system.

7 August 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
LWLi-Min Wang
Li-Min Wang
CYChangyong Yang
Changyong Yang
XSXing Sun
Xing Sun
YTYunan Tian
Yunan Tian
JZJieqiong Zhang
Jieqiong Zhang
CLCheng Liao
Cheng Liao
Activation of CD40, a pivotal component of immune oncology, could facilitate the infiltration of immune cells into the tumor microenvironment. In this investigation, we characterized SHR-2005, a second-generation CD40 agonistic mAb, as a potential candidate for cancer immune therapy. Our results showed that SHR-2005 possessed high affinity in binding to both human and rhesus CD40 and could effectively compete with CD40L for CD40 binding. Notably, SHR-2005 was engineered to exert a strong affinity for human FcγRIIb, consistent with its observed Fc receptor–dependent agonistic activity. Treatment with SHR-2005 led to robust activation of the CD40 signaling pathway and subsequent immune response. The murine surrogate SHR-2005–mIgG1 exhibited potent inhibition of tumor growth in the MC38 allograft model and showed enhanced antitumor efficacy in combination with the anti–PD-L1 antibody. Furthermore, intravesical instillation of SHR-2005–mIgG1 also increased the populations of dendritic cells (DC), CD3+ T cells, and CD4+ T cells in bladder tissue. No obvious abnormality except for a reversible local irritation was observed via intravesical instillation. Notably, SHR-2005 induced significantly lower IL-6 secretion than the APX005M analogue in human peripheral blood mononuclear cells, indicating a favorable safety profile. In conclusion, the CD40 agonistic antibody SHR-2005 was highly reliant on FcγR for agonistic activation and exhibited promising potential for clinical development as monotherapy or in combination with the anti–PD-L1 antibody for the treatment of solid tumors. Based on promising efficacy and tolerance in preclinical studies, SHR-2005 is currently being evaluated in an ongoing phase I clinical trial for the intravesical treatment of high-risk non–muscle-invasive bladder cancer.

3 November 2025
Verified
Other
Open access
LWLi-Min Wang
Li-Min Wang
CYChangyong Yang
Changyong Yang
XSXing Sun
Xing Sun
YTYunan Tian
Yunan Tian
JZJieqiong Zhang
Jieqiong Zhang
CLCheng Liao
Cheng Liao
Pharmacokinetics parameters in rhesus after single intravenous injection of SHR-2005.

3 November 2025
Verified
Other
Open access
LWLi-Min Wang
Li-Min Wang
CYChangyong Yang
Changyong Yang
XSXing Sun
Xing Sun
YTYunan Tian
Yunan Tian
JZJieqiong Zhang
Jieqiong Zhang
CLCheng Liao
Cheng Liao
SHR-2005 exhibited superior activation of DCs, B, and T cells versus 9E5 in vitro.

3 November 2025
Verified
Other
Open access
LWLi-Min Wang
Li-Min Wang
CYChangyong Yang
Changyong Yang
XSXing Sun
Xing Sun
YTYunan Tian
Yunan Tian
JZJieqiong Zhang
Jieqiong Zhang
CLCheng Liao
Cheng Liao
Activation of CD40, a pivotal component of immune oncology, could facilitate the infiltration of immune cells into the tumor microenvironment. In this investigation, we characterized SHR-2005, a second-generation CD40 agonistic mAb, as a potential candidate for cancer immune therapy. Our results showed that SHR-2005 possessed high affinity in binding to both human and rhesus CD40 and could effectively compete with CD40L for CD40 binding. Notably, SHR-2005 was engineered to exert a strong affinity for human FcγRIIb, consistent with its observed Fc receptor–dependent agonistic activity. Treatment with SHR-2005 led to robust activation of the CD40 signaling pathway and subsequent immune response. The murine surrogate SHR-2005–mIgG1 exhibited potent inhibition of tumor growth in the MC38 allograft model and showed enhanced antitumor efficacy in combination with the anti–PD-L1 antibody. Furthermore, intravesical instillation of SHR-2005–mIgG1 also increased the populations of dendritic cells (DC), CD3+ T cells, and CD4+ T cells in bladder tissue. No obvious abnormality except for a reversible local irritation was observed via intravesical instillation. Notably, SHR-2005 induced significantly lower IL-6 secretion than the APX005M analogue in human peripheral blood mononuclear cells, indicating a favorable safety profile. In conclusion, the CD40 agonistic antibody SHR-2005 was highly reliant on FcγR for agonistic activation and exhibited promising potential for clinical development as monotherapy or in combination with the anti–PD-L1 antibody for the treatment of solid tumors. Based on promising efficacy and tolerance in preclinical studies, SHR-2005 is currently being evaluated in an ongoing phase I clinical trial for the intravesical treatment of high-risk non–muscle-invasive bladder cancer.